Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sergio Sánchez-Fernández"'
Autor:
Sergio Sánchez-Fernández, Eva María Lasa, Soledad Terrados, Francisco Javier Sola-Martínez, Sara Martínez-Molina, Marta López de Calle, Paula Cabrera-Freitag, María José Goikoetxea
Publikováno v:
JMIR Pediatrics and Parenting, Vol 7, p e54163 (2024)
BackgroundMilk and egg allergies significantly impact the quality of life, particularly in children. In this regard, food oral immunotherapy (OIT) has emerged as an effective treatment option; however, the occurrence of frequent adverse reactions pos
Externí odkaz:
https://doaj.org/article/dfce18e847f74d909a176befe9e1a35c
Publikováno v:
Allergy. 78:603-605
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbba9e132db47c0c7a55a63b1e0b600b
https://doi.org/10.1111/all.15592
https://doi.org/10.1111/all.15592
Autor:
María de la Paz Morales‐Palacios, Jorge M. Núñez‐Córdoba, Eduardo Tejero, Óscar Matellanes, Paola Leonor Quan, Álvaro Carvallo, Sergio Sánchez‐Fernández, Maite Urtasun, Carla Larrea, María Teresa Íñiguez, Rosa Giménez, Maria José Goikoetxea, Carmen M. D'Amelio, Marta Ferrer, Gabriel Gastaminza
Publikováno v:
Allergy. 78:299-301
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7057c96078d27665dc8bb25d3ff48513
https://doi.org/10.1111/all.15474
https://doi.org/10.1111/all.15474
Fenebrutinib is an orally administered, selective and reversible BTK inhibitor. Metz et al recently published a double-blind, placebo-controlled, phase 2 trial where fenebrutinib (50mg daily, 150mg daily or 200mg twice-daily) or placebo were randomly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27ce98b5ce8e7249f9927d8d95fb7f0f
https://doi.org/10.22541/au.166572185.54015242/v1
https://doi.org/10.22541/au.166572185.54015242/v1
